Breast Cancer Sample Clauses

Breast Cancer. Benefits for Covered Services in relation to Breast Cancer are provided, including, screening and diagnosis of breast cancer, consistent with generally accepted medical practice and scientific evidence. Treatment for breast cancer includes coverage for prosthetic devices or reconstructive surgery to restore and achieve symmetry for the patient incident to a mastectomy. See “Prosthetics and Devices,” as well as “Inpatient Facility Services,” and “Preventive Services” for additional details. Please see “Therapy Services” later in this section. Please see “Therapy Services” later in this section. Please see “Dental Services” later in this section. Please see “Vision Services” later in this section. Benefits include coverage for services given to You as a participant in an approved Clinical Trial if the services are Covered Services under this Plan, including routine patient care costs. Routine patient care costs include the costs associated with the provision of health care services, including drugs, items, devices, and services that would otherwise be covered under the plan or contract if those drugs, items, devices, and services were not provided in connection with an approved clinical trial program, including: • Health care services typically provided absent a clinical trial. • Health care services required solely for the provision of the investigational drug, item, device, or service. • Health care services provided for the prevention of complications arising from the provision of the investigational drug, item, device, or service. • Health care services needed for the reasonable and necessary care arising from the provision of the investigational drug, item, device, or service, including the diagnosis or treatment of the complications. Routine patient care costs do not include the costs associated with the provision of any of the following: • Drugs or devices that have not been approved by the federal Food and Drug Administration and that are associated with the clinical trial. • Services other than health care services, such as travel, housing, companion expenses, and other nonclinical expenses, that an Enrollee may require as a result of the treatment being provided for purposes of the clinical trial. • Any item or service that is provided solely to satisfy data collection and analysis needs and that is not used in the clinical management of the patient. • Health care services that, except for the fact that they are being provided in a clinical trial, ...

Breast Cancer. Benefits for Covered Services in relation to Breast Cancer are provided, including, screening and diagnosis of breast cancer, consistent with generally accepted medical practice and scientific evidence. Treatment for breast cancer includes coverage for prosthetic devices or reconstructive surgery to restore and achieve symmetry for the patient incident to a mastectomy. See “Prosthetics and Devices,” as well as “Inpatient Facility Services,” and “Preventive Services” for additional details. Please see “Therapy Services” later in this section. Please see “Therapy Services” later in this section. Please see “Dental Services” later in this section. Please see “Vision Services” later in this section. We cover Medically Necessary chiropractic services provided by a person properly licensed pursuant to the Chiropractic Initiative Act or the Osteopathic Initiative Act.

Breast Cancer. Of all cancers, breast cancer ranks first among mortality causes for Mexican women. In 2007, an average of 16.4 out of 100,000 women over 25 years did not survive breast cancer. In this case, the highest averages can be found in states with high level health care. The poor states show a low average of women dying of breast cancer (INEGI, 2009c: 65). It is not clear why the situation is so different compared to cervical uterine cancer. It could be due to a lack of screening for breast cancer. Women in these regions might die from breast cancer without knowing the real cause of their death. It is also possible that their way of life protects against breast cancer. Some factors limit the chances of having breast cancer, for example having had children, having had a first child before 30 years of age, having breast fed children, or not having used the pill too young or for long periods (WHO, 2014). Women with low socio-economic backgrounds have on average more children than women in higher social classes; they are on average younger when they have their first child; they breast feed their children for long periods; and they use less contraceptive pills. These factors could to some extent explain the lower prevalence of breast cancer in indigenous communities. It must be pointed out that in an educational context, the screening of breast cancer is not discussed as such in the SEP 6th grade natural sciences text book. It is treated in a section called ‘Un dato interesante’ (‘An interesting fact’) (SEP, 2011: 33). A better approach might be necessary to address the main mortality cause of Mexican women. 6. The Need for Sexual Education and Prevention

Breast Cancer. For each Product developed by LILLY for [ * ] -------------- treatment of breast cancer LILLY shall pay to MEGABIOS: (1) [ * ] (2) [ * ] [ * ] Certain information on this page has been omitted and filed separately with the Commission. Confidential Treatment has been requested with respect to the omitted portions. (3) [ * ] (4) [ * ]

Breast Cancer. Goals: Objective 1:

Breast Cancer. First visit to PC* GP vs Patient (n=928) -5.9 44 24 32 0.90 (0.89, 0.91) GP vs Patient (n=1790) 1.4 24 35 41 0.94 (0.93, 0.94) Registry and Patient (n=2645) -5.9 15 38 47 0.98 (0.98, 0.98) Diagnosis Registry and GP (n=1822) -5.7 27 39 34 0.97 (0.97, 0.97) SP and Registry (n=1001) -4.9 17 61 23 0.99 (0.98, 0.99) SP and Patient (n=989) -1.0 16 49 35 0.93 (0.93, 0.94)

Breast Cancer. Facts and Statistics

Breast Cancer. First visit to PC* GP vs Patient (n=928) -5.9 44 24 32 0.90 (0.89, 0.91) GP vs Patient (n=1790) 1.4 24 35 41 0.94 (0.93, 0.94) Registry and Patient (n=2645) -5.9 15 38 47 0.98 (0.98, 0.98) Diagnosis Registry and GP (n=1822) -5.7 27 39 34 0.97 (0.97, 0.97) SP and Registry (n=1001) -4.9 17 61 23 0.99 (0.98, 0.99) SP and Patient (n=989) -1.0 16 49 35 0.93 (0.93, 0.94) Treatment SP and Patient (n=984) 2.4 62 15 23 0.89 (0.88, 0.90) Colorectal cancer First visit to PC* GP vs Patient (n=865) -3.2 24 20 56 0.89 (0.88, 0.91 ) GP vs Patient (n=1462) 1.7 16 30 55 0.95 (0.94,0.95) Registry and Patient (n=2133) -4.5 20 27 53 0.96 (0.96,0.96) Diagnosis Registry and GP (n=1517) -5.0 28 28 44 0.96 (0.96,0.97) SP and Registry (n=835) -5.1 19 51 30 0.96 (0.96,0.97) SP and Patient (n=813) -0.6 9 42 49 0.94 (0.93,0.95) Treatment SP and Patient (n=785) 3.2 55 19 26 0.91 (0.90, 0.92) First visit to PC GP vs Patient (n=669) 0.03 18 19 64 0.90 (0.88, 0.91 ) GP vs Patient (n=1024) 11.9 8 22 69 0.93 (0.92, 0.94) Registry and Patient (n=1449) 4.0 4 21 74 0.96 (0.96,0.97) Diagnosis Registry and GP (n=868) -9.9 23 25 53 0.96 (0.96,0.97) SP and Registry (n=452) -10.7 24 32 44 0.97 (0.96,0.97) SP and Patient (n=575) 7.7 5 30 65 0.93 (0.92,0.94) Treatment SP and Patient (n=509) 2.4 45 24 31 0.94 (0.93,0.95)

Breast Cancer. Breast cancer is one of the most commonly diagnosed types of cancer which despite medical advances in the recent years, represents one of the leading causes of cancer related deaths among women (Jemal et al., 2010). The 5 year relative survival rate is almost 100% for early stage tumour but dramatically drops to 21% for stage IV patients highlighting the fact that early stage tumours can be adequately treated while the management of late stage diagnoses remains challenging (Xxxxx et al., 2007). A combination of genetic and environmental factors influence the development of breast cancer including mutations on the BRCA1 and BRCA genes, increasing age, obesity, alcohol and oral contraceptives (Xxxxx and Xxxxxxx, 2016). Breast cancer is widely recognised as a very heterogeneous disease with distinct subtypes characterised by specific molecular markers and clinical outcomes (Xxxxxx et al., 2014). Tumours marked by increased expression of oestrogen (ER) and progesterone (PR) receptors have a more differentiated appearance and are thought to be hormonally regulated as they respond better to drugs targeting hormone receptors such as Tamoxifen (Xxxxxxx et al., 2004). Amplification of the human epidermal growth factor 2 (HER2) receptor is found in up to 30% of breast tumours and it is associated with aggressive disease and poor clinical outcomes (Xxxxxx et al., 2014). Nonetheless, the development of targeted therapies such as the monoclonal antibody Trastuzumab and tyrosine kinase inhibitor Lapatinid have significantly improved outcomes (Xxxxxx et al., 2014). Tumours lacking hormone and HER2 receptors are grouped under the disease spectrum known as triple negative breast cancer (TNBC) (Xxxxxxx et al., 2010). 1.1.1 Triple negative breast cancer

Breast Cancer. Discuss Breast Cancer Awareness and make sure the patient is aware of the Breast Cancer Screening Program so that when the Practice’s patients come up for the three yearly mammograms, the patient might be more likely to attend. Provide Breast Cancer leaflets to appropriate patients.